MCM
BLUE

Masters Capital Management’s bluebird bio BLUE Stock Holding History

Masters Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,720
Closed -$14.6M – 56
2018
Q3 		$14.6M Buy
+7,720
New +$15.9M 0.36% 57

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Masters Capital Management's BLUE Position: Q1 2025 in Review

Masters Capital Management sold out of bluebird bio (BLUE) in Q1 2025, closing a stake of 48,750 shares — an estimated $407K sold.

Masters Capital Management first reported a position in BLUE in Q4 2017 and held it in 9 quarters. The position peaked at $45.2M in Q2 2018. 85 funds tracked by Wall St. Rank hold BLUE as of Q1 2025.

  • Masters Capital Management reported no remaining bluebird bio position as of Q1 2025 after selling out during the quarter.
  • Masters Capital Management sold 48,750 bluebird bio shares in Q1 2025, an estimated $407K.
  • Masters Capital Management first reported a position in bluebird bio in Q4 2017 and held it in 9 quarters.
  • Masters Capital Management's bluebird bio position peaked at $45.2M in Q2 2018.
  • 85 funds tracked by Wall St. Rank held bluebird bio as of Q1 2025.

Based on Masters Capital Management's 13F filing for Q1 2025, filed 15 May 2025.